Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine Introduction
Notice bibliographique
Résumé
Importance: Human papillomavirus (HPV) vaccine clinical trials demonstrate high vaccine efficacy, but postlicensure population-level effectiveness data are needed to inform vaccination and cancer-prevention recommendations and policies. Little is known about effectiveness in adolescent girls and young adult women at high risk for HPV-related cancers or after 9-valent HPV vaccine (9vHPV) introduction. Objective: To examine effectiveness and herd protection over the first 17 years after HPV vaccine introduction in adolescent girls and young women at increased risk for HPV infection and related cancers. Design, Setting, and Participants: This cross-sectional study analyzed data from 6 surveillance studies from 2006 to 2023. A consecutive sample of sexually experienced adolescent girls and young women aged 13 to 26 years was recruited from clinical settings. Exposure: Participants were stratified by HPV vaccination status; those who received at least 1 vaccine dose were defined as vaccinated. Main Outcomes and Measures: Effectiveness and herd protection were assessed by comparing proportions of vaccinated and unvaccinated participants positive for at least 1 type in the 2-valent vaccine (2vHPV), 4-valent vaccine (4vHPV), and 9vHPV in each of 6 studies. The prevalence of vaccine-type HPV was compared in vaccinated participants from surveillance studies 2 through 6 vs participants recruited in surveillance study 1, all of whom were unvaccinated. Inverse probability of treatment weighting with propensity score was used to balance between-wave differences in participant characteristics. Results: Of 2335 participants (mean [SD] age, 18.9 [2.7] years; 1526 African American [65.4%], 13 Asian [0.6%], 6 Native American [0.3%], 582 White [24.9%], and 151 multiracial [6.5%]; 173 Hispanic [7.4%]), 1195 participants (51.2%) reported a sexually transmitted infection history and 1843 participants (78.9%) reported 2 or more male sex partners. Vaccination rates increased from 0 of 371 participants to 330 of 402 participants (82.1%) from 2006 to 2023. Among vaccinated participants, positivity decreased from 93 of 371 participants (27.7%) to 1 of 330 participants (0.4%) for 2vHPV (relative difference, 98.4%), 118 participants (35.4%) to 3 participants (2.1%) for 4vHPV (relative difference, 94.2%), and 163 participants (48.6%) to 21 participants (11.8%) for 9vHPV (relative difference, 75.7%). Among unvaccinated participants, positivity decreased from 93 of 371 participants (25.8%) to 3 of 72 participants (7.3%) for 2vHPV (relative difference, 71.6%), 118 participants (25.3%) to 4 participants (6.1%) for 4vHPV (relative difference, 75.8%), and 163 participants (42.7%) to 13 participants (31.1%) for 9vHPV (relative difference, 27.2%). For positivity rates, counts are raw numbers and percentages are propensity score adjusted. Adjusted logistic regression demonstrated significant reductions in the odds of at least 1 HPV type in the 2vHPV and 4vHPV among all (adjusted odds ratio [aOR], 0.03; 95% CI, 0.01 to 0.07 and aOR, 0.06; 95% CI, 0.03 to 0.10, respectively), vaccinated (aOR, 0.01; 95% CI, <0.01 to 0.05 and aOR, 0.04; 95% CI, 0.02 to 0.08, respectively), and unvaccinated (aOR, 0.23; 95% CI, 0.08 to 0.63 and aOR, 0.19; 95% CI, 0.07 to 0.52, respectively) participants and in the 9vHPV among all (aOR, 0.22; 95% CI 0.16 to 0.31) and vaccinated (aOR, 0.14; 95% CI 0.09 to 0.21) participants. Conclusions and Relevance: In this study, population-level effectiveness and herd protection were robust 17 years after HPV vaccine introduction, even in sexually experienced adolescent girls and young women at relatively high risk for HPV who may not have received the full vaccination series.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».